“…[2][3][4]11,18,33,[39][40][41] Although the 2012 Appropriate Use Criteria has included the implementation of MMS for MIS, the technique is still underused despite the potential advantages. 7,42 For instance, based on Medicare data until 2013, only 0.3%-3.5% of Mohs cases in the United States were performed on melanomas, 38,43,44 and rates of utilization of Mohs for MIS do not seem to have increased. 7 However, given the potential advantages of Mohs and its controversial role in the management of melanoma, the authors felt it was timely to compare its use in relation with the oncologic standard of care in the context of the emerging data.…”